ReviewEuropean respiratory review : an official journal of the European Respiratory Society2019
What have we learned from basic science studies on idiopathic pulmonary fibrosis?
Review in European respiratory review : an official journal of the European Respiratory Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 56 citations in OpenAlex.
- Human Embryonic Stem Cell-Derived Immunity-And-Matrix-Regulatory Cells Attenuate Pulmonary Fibrosis via MMP1-Mediated Collagen Degradation.Cell proliferation · 2026Article
- Shensiqigui tablets alleviate bleomycin-induced pulmonary fibrosis by inhibiting the hedgehog/wnt-β-catenin pathway.Histology and histopathology · 2025Article
- Dian sanguis draconis improves pulmonary fibrosis by activating autophagy to regulate the PA/PAI-1 balance.Histology and histopathology · 2025Article
- Optimized Synthetic Flavonols Support Senescence Clearance and Lung Fibrosis Resolution.ACS pharmacology & translational science · 2025Article
- Involvement of naïve T cells in the pathogenesis of osimertinib-induced pneumonitis.Scientific reports · 2025Article
- Deregulated immune cell recruitment orchestrated by c-MET impairs pulmonary inflammation and fibrosis.Respiratory research · 2024Article
- Transcriptomics in idiopathic pulmonary fibrosis unveiled: a new perspective from differentially expressed genes to therapeutic targets.Frontiers in immunology · 2024Article
- Latent inter-organ mechanism of idiopathic pulmonary fibrosis unveiled by a generative computational approach.Scientific reports · 2023Article
- Animal models of acute exacerbation of pulmonary fibrosis.Respiratory research · 2023Review
- Overexpression of KLF4 Suppresses Pulmonary Fibrosis through the HIF-1α/Endoplasmic Reticulum Stress Signaling Pathway.International journal of molecular sciences · 2023Article
- Oxymatrine inhibits TGF‑β1‑mediated mitochondrial apoptotic signaling in alveolar epithelial cells via activation of PI3K/AKT signaling.Experimental and therapeutic medicine · 2023Article
- Mass cytometry identifies characteristic immune cell subsets in bronchoalveolar lavage fluid from interstitial lung diseases.Frontiers in immunology · 2023Article
- Genetics in Idiopathic Pulmonary Fibrosis: A Clinical Perspective.Diagnostics (Basel, Switzerland) · 2022Review
- Effect of Hypoxia on Pulmonary Endothelial Cells from Bleomycin-Induced Pulmonary Fibrosis Model Mice.International journal of molecular sciences · 2022Article
- Lung Injury Induces Alveolar Type 2 Cell Hypertrophy and Polyploidy with Implications for Repair and Regeneration.American journal of respiratory cell and molecular biology · 2022Article
- Monogenic gene variants in lung transplant recipients with usual interstitial pneumonia.ERJ open research · 2022Article
- Article
- Integrative analysis of lung molecular signatures reveals key drivers of idiopathic pulmonary fibrosis.BMC pulmonary medicine · 2021Article
- Molecular Pathogenesis of Pulmonary Fibrosis, with Focus on Pathways Related to TGF-β and the Ubiquitin-Proteasome Pathway.International journal of molecular sciences · 2021Review
- Extracellular matrix proteins produced by stromal cells in idiopathic pulmonary fibrosis and lung adenocarcinoma.PloS one · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic pulmonary fibrosis is a fatal age-related lung disease characterised by progressive and irreversible scarring of the lung. Although the details are not fully understood, there has been tremendous progress in understanding the pathogenesis of idiopathic pulmonary fibrosis, which has led to the identification of many new potential therapeutic targets. In this review we discuss several of these advances with a focus on genetic susceptibility and cellular senescence primarily affecting epithelial cells, activation of profibrotic pathways, disease-enhancing fibrogenic cell types and the role of the remodelled extracellular matrix.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.